Dr. Fauci at IAS 2015: Comprehensive global prevention can end HIV/AIDS pandemic

July 21, 2015

Although much progress has been made in combating the global HIV/AIDS pandemic, to halt new infections and end the pandemic, a combination of non-vaccine and vaccine prevention modalities will be needed. Even with these tools, significant implementation gaps must be closed, including the targeted deployment of proven prevention methods to the populations that need them most, says Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. Dr. Fauci addressed a special session at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada.

Dr. Fauci will describe how proven medical interventions have been successfully applied to a range of prevention strategies, including antiretroviral therapy (ART), medical male circumcision, daily pre-exposure prophylaxis (PrEP) and treatments that prevent mother-to-child HIV transmission. He also will review how treatment of HIV-infected people early in the course of their infection can dramatically reduce the risk of transmitting HIV to an uninfected sexual partner, while simultaneously protecting the health of the infected individual. Although these interventions can dramatically reduce the rate of HIV infection, some individuals find it difficult to adhere to ART, which presents obstacles to optimal implementation of these programs.

Several approaches towards the development of an HIV vaccine are currently being pursued, Dr. Fauci notes. The Pox-Protein Public-Private Partnership (P5), of which NIAID is a member, is exploring strategies in South African trials to amplify the encouraging results from RV 144, an HIV vaccine clinical trial in Thailand that resulted in the first modest signal of efficacy. Scientists also are investigating the potential use of broadly neutralizing antibodies directed against HIV which are elicited in natural infection in some HIV-infected individuals. These antibodies already are being tested for use via passive transfer in treatment and prevention of transmission. Scientists in pursuit of an HIV vaccine are building on this work, designing techniques to elicit these antibodies through sequential stimulation of the immune system with specifically designed immunogens.

Better application of proven prevention technologies can help drive down the global incidence of HIV. If these methods can be combined with an effective vaccine, the end of the HIV/AIDS pandemic could be within reach, according to Dr. Fauci. However, to realize that potential, substantial implementation gaps will need to be closed. For example, evidence shows that HIV risk is not uniformly distributed; certain high-transmission areas have disproportionately elevated rates of incidence as compared to neighboring districts. Dr. Fauci will discuss that by focusing on these areas, understanding the drivers of HIV risk and deploying prevention technologies, HIV transmission could be decreased dramatically, finally halting the spread of HIV.

Dr. Fauci spoke in a special session of the 8th International AIDS Society Conference on HIV Pathogenesis in Vancouver, Canada, delivering remarks on "Progress and Challenges in HIV Prevention: Vaccine and Non-Vaccine Approaches." A videocast of his lecture will be posted on the IAS website, http://IAS2015.org/.

A Fauci. Progress and challenges in HIV prevention: vaccine and non-vaccine approaches. Program number MOSS01.


NIAID Director Anthony S. Fauci, M.D., is available for comment.


To schedule interviews, please contact Anne Rancourt, (301) 402-1663, anne.rancourt@nih.gov.

NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.NIH...Turning Discovery Into Health®

NIH/National Institute of Allergy and Infectious Diseases

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.